To the editor:

Chiam et al. \[[@b1-inj-1836096-048]\] stated that prostate cancer (PCa) is a major global health problem that imposes a significant economic burden in nations with an aging population. The annual percentage change (APC) of the incidence of PCa in Korean men was 13.7% from 1999 to 2009, and APC of mortality rates was 17.5% from 1999 to 2002 \[[@b2-inj-1836096-048]\]. The widespread use of prostate-specific antigen (PSA)-based screening testing (PSA-ST) leads to an increased incidence of PCa because it enables the earlier detection of occult or asymptomatic disease \[[@b3-inj-1836096-048]-[@b5-inj-1836096-048]\].

As PSA is not a specific marker of PCa \[[@b1-inj-1836096-048]\], recommendations on PSA-ST for PCa vary in terms of the screening age and interval \[[@b6-inj-1836096-048],[@b7-inj-1836096-048]\]. Of note, the 2012 U.S. Preventive Services Task Force guideline \[[@b8-inj-1836096-048]\] recommended against routine screening for PCa, because the benefits of PSA-ST for PCa do not outweigh the harms.

The harms of PSA-ST can be summarized as overdiagnosis, unnecessary biopsies with potential associated adverse effects, anxiety, and excessive treatment \[[@b7-inj-1836096-048],[@b9-inj-1836096-048],[@b10-inj-1836096-048]\]. As such, the most serious limitation of PSA-ST as a screening modality is the fact that PSA levels can be elevated in patients with benign prostatic hyperplasia or prostatitis, as well as in PCa patients \[[@b7-inj-1836096-048],[@b11-inj-1836096-048]\]. This phenomenon may give rise to overdiagnosis, resulting in overtreatment \[[@b1-inj-1836096-048],[@b6-inj-1836096-048],[@b12-inj-1836096-048],[@b13-inj-1836096-048]\]. In addition to this, PSA-ST has very poor sensitivity, specificity, and predictive values because there are no absolute cutoff PSA levels defining PCa \[[@b1-inj-1836096-048],[@b13-inj-1836096-048]\]. Thus, Lee et al. \[[@b14-inj-1836096-048]\] concluded that PSA-ST alone did not increase earlystage PCa detection or reduce mortality.

To overcome these limitations of PSA-ST, PSA velocity \[[@b15-inj-1836096-048]\], testing for 4 prostate-specific kallikreins \[[@b3-inj-1836096-048]\], the prostate health index test \[[@b16-inj-1836096-048]\], the percentage of free PSA \[[@b17-inj-1836096-048]\], and tests for noncoding prostate-tissue-specific RNA \[[@b18-inj-1836096-048]\] have been introduced. However, these PSA derivatives may be impractical or only helpful in specific situations \[[@b1-inj-1836096-048],[@b7-inj-1836096-048]\]. Thus, novel biomarkers capable of replacing serum PSA for PCa screening must be investigated \[[@b19-inj-1836096-048]-[@b22-inj-1836096-048]\]. In addition, reliable and accurate biomarkers for discriminating between indolent and aggressive tumors at the early stage of PCa are needed \[[@b23-inj-1836096-048]\].

As age, race, and environment are known to be the main risk factors for PCa, epigenetic studies investigating the carcinogenesis of PCa through gene-environment interactions have been conducted \[[@b1-inj-1836096-048],[@b24-inj-1836096-048]\]. Current evidence suggests that epigenetic alterations of aberrant DNA methylation, histone modifications, and noncoding microRNA are associated with the carcinogenesis of PCa \[[@b25-inj-1836096-048]-[@b28-inj-1836096-048]\]. Thus, potential biomarkers related to a high frequency of epigenetic changes may improve the sensitivity and specificity of the diagnosis (including early detection) and prognosis of PCa \[[@b1-inj-1836096-048],[@b13-inj-1836096-048],[@b25-inj-1836096-048],[@b27-inj-1836096-048],[@b29-inj-1836096-048]\].

Chiam et al. \[[@b1-inj-1836096-048]\] tabulated the epigenetic biomarkers associated with the diagnosis, prognosis, and treatment response of PCa. Furthermore, Yegnasubramanian \[[@b13-inj-1836096-048]\] suggested that methylation in the regulatory regions of *GSTP1, APC, PTGS2, RARB*, and *RASSF1A* may be epigenetic biomarkers for PCa screening. In particular, measurements of *GSTP1* promoter methylation in plasma, serum, whole blood, urine, ejaculate, or prostatic secretions may complement PSA-ST for PCa based on a meta-analysis of 22 studies \[[@b30-inj-1836096-048]\]. However, all those studies were case-control studies with a small sample size. Thus, a population-based cohort study in asymptomatic men with a large sample size is needed to evaluate the effectiveness of *GSTP1* for the early detection of PCa and/or the identification of aggressive tumors.

In conclusion, the controversies regarding PSA-ST have led to the need for a more accurate biomarker suitable for the early detection of PCa \[[@b31-inj-1836096-048]\]. This unmet need could be satisfied by epigenetic biomarkers related to the pathogenesis of PCa \[[@b13-inj-1836096-048],[@b29-inj-1836096-048]\].

However, potential epigenetic markers require further research to be validated for screening in diverse populations \[[@b25-inj-1836096-048],[@b32-inj-1836096-048]\]. Further studies may lead to the development of epigenetic markers that could replace, rather than complement, PSA-ST due to advantages in sensitivity.
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